x

Posted 07 January, 2022

Sorrento Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker None:None in a 8-K filed on 07 January, 2022.


  Following Mr. Asghar's unexpected death, the Company's Board of Directors (the "Board") has appointed Henry Ji, Ph.D., the Company's Chairman of the Board, President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Sorrento Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Market Cap
$11.0M
View Company Details
Sorrento Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Sorrento Therapeutics, Inc. (the "Company") is saddened to report that Najjam Asghar, the Company's Senior Vice President and Chief Financial Officer, passed away unexpectedly on January 6, 2022. Mr. Asghar had served as the Company's Senior Vice President and Chief Financial Officer since August 2020 and as the Company's Chief Accounting Officer from June 2019 to August 2020. He will be greatly missed and the Company extends its sincere condolences to Ms. Asghar's family.


Following Mr. Asghar's unexpected death, the Company's Board of Directors (the "Board") has appointed Henry Ji, Ph.D., the Company's Chairman of the Board, President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer. Upon commencement of his appointment, Dr. Ji assumed the duties of the Company's principal financial officer and principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal. The biographical information for Dr. Ji required by Item 401 of Regulation S-K was previously disclosed under the heading "Proposal 1: Election of Directors" in the Company's definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on October 5, 2021 (the "Proxy Statement"), and such information is incorporated herein by reference. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Dr. Ji other than compensation arrangements with Dr. Ji and a customary indemnification agreement between the Company and Dr. Ji, each of which is described in the Proxy Statement.